Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 11Neoplasms 2Mycosis Fungoides 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Mesothelioma, Malignant 1Melanoma 1Lymphomatoid Papulosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Busulfan 2Biopsy 2talimogene laherparepvec 1pembrolizumab 1fludarabine 1duvelisib 1Vincristine 1Transplantation 1Sirolimus 1Radiotherapy 1Prednisone 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Etoposide 1Cyclosporine 1Brentuximab Vedotin 1Blood Specimen Collection 1Aclarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × Brentuximab Vedotin × 90 days × Clear all
NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
58 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡